secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0000899923-24-000045
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics discontinues part two of GeneSight study; control group deemed unreliable
--------------------------------------------------------------------------------

- Part one (April 2024) showed 29% drop in all-cause hospitalizations and 39% drop in psychiatric-related hospitalizations 180 days post-GeneSight.
- Part two aimed to compare GeneSight patients vs. matched non-GeneSight control; significant baseline disparities made control group non-viable.
- Company concluded data comparing the two groups were not reliable and halted the analysis.
- GeneSight's causal role in hospitalization reduction remains unconfirmed without a valid control group.
- Company plans to publish full part one results in the near future.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000045/0000899923-24-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000045/mygn-20240904.htm
  HTML page:      https://secwatch.observer/filing/0000899923-24-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer